| B72.3 |
sTn (TAG-72) |
adenocarcinomas (breast, colon, lung) |
IgG1 |
bound strongly to consecutive sTn antigens (sTn2 and sTn3),
but weakly to monovalent antigens (sTn1) |
(154) |
| CC49 |
sTn (TAG-72) |
adenocarcinomas (breast,
colon, lung) |
IgG1 |
usually more effective
in combination with B72.3 |
(155), (156) |
| TKH2, HB-sTn1 |
sTn |
colorectal and other epithelial neoplasms |
|
stronger recognition of aggregation sTn antigens than that
of individual antigen |
(157) |
| MLS102 |
sTn (α2,6) |
cancers
of intestine, esophagus and ovary |
IgG |
identifying clusters of sTn antigens |
(158) |
| LLU9B4 |
sTn |
colonic adenocarcinoma |
IgG |
highly sensitive to colon cancer |
(159) |
| 3P9 |
sTn |
colonic adenocarcinoma |
IgM |
effective inhibition on tumor growth with
therapeutic potential |
(160) |
| NCC-LU-35, NCC-LU-81 |
Tn |
adenocarcinomas (lung) |
IgM |
in addition
to Tn antigen, the cross-reaction with blood group A and AB antigen, but the cross-reaction with
NCC-LU-81 weaker, and the two are similar in other aspects |
(103) |
| 83D4 |
Tn |
breast, ovarian,
endometrial, pancreatic and colonic adenocarcinomas. |
IgM |
recognizing Tn antigen, but unclear on tumor cell
toxicity |
(161) |
| CU-1 |
Tn |
squamous cell carcinoma; gastric,
colonic, breast, and lung
carcinoma; leukemia |
IgG3 |
no cross-reaction
with blood group antigens |
(106) |
| MLS 128 |
Tn |
colonic adenocarcinoma |
IgG3 |
recognizing primarily the aggregated Tn
antigens (Tn2, Tn3),
which inhibits the growth of some cancer cell lines and has therapeutic
potential |
(105), (162) |
| BRIC 66 |
Tn |
adenocarcinoma |
IgM |
recognition pattern similar to NCC-LU-35,
which preferentially
responds to the blood group A antigen |
(109) |
| BRIC 111 |
Tn |
adenocarcinoma |
IgG1 |
recognition pattern similar to CU-1 and
does not react with
the blood group A antigen |
(109) |
| PMH1 |
Tn |
N/A |
IgM |
reacting with a specific peptide
sequence modified by GalNAc,
rather than relying solely on GalNAc or peptide sequence recognition |
(163) |
| KM3413 |
Tn |
colonic adenocarcinoma |
IgG1 |
recognizing the aggregated Tn 2 and Tn 3
antigens but not the
individual Tn antigen. Promising therapeutic antibody |
(110) |
| 2154F12A4 |
Tn |
breast cancer |
IgM |
inhibiting the adhesion of tumor cells and
lymphatic endothelial |
(111) |
| GOD3-2C4 |
Tn |
breast, colon, lung, ovarian and pancreas cancer |
IgG1 |
does not cross-react with GalNAc-β-O
epitope, A blood
group antigen, and therapeutic potential |
(112) |
| 237 |
Tn |
fibrosarcoma |
IgG2 |
relying on multiple and specific weak interactions between
the antibody and both the sugar and peptide moieties to ensure that
only the intact glycopeptide will be recognized. |
(164) |
